Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Versartis Inc (VSAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7607
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Versartis Inc (Versartis) is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of endocrine disorders. The company’s lead product candidate include somavaratan (VRS-317) is a recombinant human growth hormone (GHD) that is designed to reduce the burden of daily injection therapy which is used in the treatment of growth hormone deficiency in both children and adults. It utilizes half-life extension technology, a proprietary recombinant polypeptide technology for development of its products. The company serves life science industry. Versartis is headquartered in Menlo Park, California, the US.

Versartis Inc (VSAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Versartis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Versartis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Versartis Raises US$55 Million In Series E Financing 10
Versartis Secures USD12.49 Million in Series C Venture Funding 12
Versartis Raises US$20 Million In Series D Financing 13
Versartis Raises US$25 Million In Series C Financing 15
Licensing Agreements 17
Teijin Pharma Enters into Licensing Agreement with Versartis 17
Equity Offering 19
Versartis Raises USD63.4 Million in Public Offering of Shares 19
Versartis Raises USD86.3 Million in Public Offering of Shares 21
Versartis Completes IPO Of For US$145 Million 23
Versartis Inc – Key Competitors 25
Versartis Inc – Key Employees 26
Versartis Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 07, 2018: Versartis announces second quarter 2018 financial results 28
May 08, 2018: Versartis Reports First Quarter 2018 Financial Results 30
Mar 01, 2018: Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 31
Oct 26, 2017: Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33
Jul 27, 2017: Versartis Reports Second Quarter 2017 Financial Results 34
Apr 27, 2017: Versartis Reports First Quarter 2017 Financial Results 36
Feb 21, 2017: Versartis Reports Fourth Quarter 2016 Financial Results 37
Corporate Communications 39
Sep 05, 2017: Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs 39
Jun 01, 2017: Versartis Appoints Eric Dobmeier to Board of Directors 40
Apr 25, 2017: Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations 41
Mar 15, 2017: Versartis Appoints Tracy Woody as Chief Commercial Officer 42
Jan 31, 2017: Versartis announces management changes 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Versartis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Versartis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Versartis Raises US$55 Million In Series E Financing 10
Versartis Secures USD12.49 Million in Series C Venture Funding 12
Versartis Raises US$20 Million In Series D Financing 13
Versartis Raises US$25 Million In Series C Financing 15
Teijin Pharma Enters into Licensing Agreement with Versartis 17
Versartis Raises USD63.4 Million in Public Offering of Shares 19
Versartis Raises USD86.3 Million in Public Offering of Shares 21
Versartis Completes IPO Of For US$145 Million 23
Versartis Inc, Key Competitors 25
Versartis Inc, Key Employees 26
Versartis Inc, Subsidiaries 27

List of Figures
Versartis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gilead Sciences, Inc.:企業の戦略・SWOT・財務情報
    Gilead Sciences, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gilead Sciences, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Alios BioPharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Alios BioPharma Inc (Alios BioPharma), a subsidiary of Janssen Pharmaceuticals Inc is a biopharmaceutical company that discovers and develops novel therapies for treatment of viral diseases. The company offers drugs for the treatment of viral infections such as respiratory syncytial virus, i …
  • G1 Therapeutics Inc (GTHX)-製薬・医療分野:企業M&A・提携分析
    Summary G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc is a healthcare company that develops novel, and small molecule therapies. The company pipeline products include CDK4/6, trilaciclib G1T28 a drug candidate; G1T38 a potential best compound, and G1T48. It undertakes disco …
  • FP Corporation:企業の戦略・SWOT・財務情報
    FP Corporation - Strategy, SWOT and Corporate Finance Report Summary FP Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Serina Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Serina Therapeutics Inc (Serina Therapeutics) is a pharmaceutical company that develops therapeutics for cancer, neurological diseases, pain and metabolic disorders. The company’s pipeline products include SER-214, SER-227, SER-228, SER-232, and other proprietary drugs. It uses proprietary t …
  • MaaT Pharma-製薬・医療分野:企業M&A・提携分析
    Summary MaaT Pharma (MaaT) is a biotechchnology company that develop novel treatments for Gut Microbiota - dysbiosis related diseases. The company is working on two projects, which are in the developmental stage, namely, MaaT001, an innovative live frozen inoculum suspension and MaaT002, an innovati …
  • Suncor Energy Inc (SU):電力:M&Aディール及び事業提携情報
    Summary Suncor Energy Inc. (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and onshore oil and gas production; refining of crude oil and marketing of petroleum and petrochemical …
  • Repsol, S.A.:企業の戦略・SWOT・財務分析
    Repsol, S.A. - Strategy, SWOT and Corporate Finance Report Summary Repsol, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Cerus Energy Group Ltd (CEA):企業の財務・戦略的SWOT分析
    Summary Cerus Energy Group Ltd (Cerus Energy), formerly Petrostar Petroleum Corp is an oil and gas company that produces methanol, DME, and petroleum and natural gas. The company offers deep well disposal, storage and terminalling services, and well management services. Its well management services …
  • Jumboking Foods Pvt. Ltd.
    Jumboking Foods Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jumboking Foods Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Industrial Bank Of Korea:企業の戦略・SWOT・財務分析
    Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CapitaLand Ltd:戦略・SWOT・企業財務分析
    CapitaLand Ltd - Strategy, SWOT and Corporate Finance Report Summary CapitaLand Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Ferring Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ferring Pharmaceuticals Inc (Ferring), a subsidiary of Ferring International Center SA is a biopharmaceutical company that conducts research and development services. The company develops peptide-based drugs and biotechnology derived medicines. It also develops effective and patient-friendly …
  • Tokyo Broadcasting System Holdings Inc (9401):企業の財務・戦略的SWOT分析
    Tokyo Broadcasting System Holdings Inc (9401) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • GenomicTree Inc:企業の製品パイプライン分析2018
    Summary GenomicTree Inc (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung and …
  • Copa Holdings, S.A. (CPA):企業の財務・戦略的SWOT分析
    Copa Holdings, S.A. (CPA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Exact Holding N.V.:企業の戦略的SWOT分析
    Exact Holding N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • CellSeed Inc (7776):企業の製品パイプライン分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …
  • Emerson Electric Co (EMR):企業の財務・戦略的SWOT分析
    Emerson Electric Co (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cost Plus Inc:企業の戦略的SWOT分析
    Cost Plus Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆